Clinical trial results:
A Phase 3 Randomised, Double-Masked, Placebo-Controlled Study of the Pharmacokinetics of OMS302 and the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Undergoing Intraocular Lens Replacement with Phacoemulsification

Summary

EudraCT number	2012-000867-25
Trial protocol	NL AT
Global end of trial date	18 March 2013

Results information

Result version number	v1 (current)
This version publication date	26 January 2019
First version publication date	26 January 2019

Trial information

Trial identification

Sponsor protocol code	OMS302-ILR-004

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01579565
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Omeros Corporation
Sponsor organisation address	201 Elliott Ave W, Seattle, United States, 98119
Public contact	Regulatory Affairs, Novella Clinical, +44 01438221122, vvanaaken@novellaclinical.com
Scientific contact	Regulatory Affairs, Novella Clinical, +44 01438221122, vvanaaken@novellaclinical.com
Sponsor organisation name	Omeros Corporation
Sponsor organisation address	201 Elliott Avenue West, Seattle, United States, 98119
Public contact	Soyoung Han, Omeros Corporation, 011 12066765000, shan@omeros.com
Scientific contact	Andrea Kessler, Omeros Corporation, 011 12066765000, akessler@omeros.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 April 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 January 2013
Global end of trial reached?	Yes
Global end of trial date	18 March 2013
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The co-primary objectives of this study are to evaluate the effect of OMS302 compared to placebo when administered in irrigation solution during phacoemulsification and intraocular lens replacement on: Intraoperative pupil diameter and Pain during the early postoperative period.

Protection of trial subjects:

N/A

Background therapy:

Preoperative mydriatics

Evidence for comparator:

None

Actual start date of recruitment	28 February 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 12
Country: Number of subjects enrolled	United States: 404
Worldwide total number of subjects	416
EEA total number of subjects	12

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	107
From 65 to 84 years	295
85 years and over	14

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

N/A

Period 1

Period 1 title	Randomized
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Monitor, Data analyst, Assessor, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	OMS302

Arm description:

OMS302 diluted in irrigation solution

Arm type	Experimental
Investigational medicinal product name	OMS302
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for intraocular irrigation
Routes of administration	Intraocular use

Dosage and administration details:

For administration to patients, 4.4 mL of the drug product are added to a 500-mL bottle of commercially available balanced saline solution (BSS) through a syringe filter, resulting in 4.0 mL of the drug product in the 500-mL bottle

Arm title	Placebo

Arm description:

Placebo diluted in irrigation solution

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for intraocular irrigation
Routes of administration	Intraocular use

Dosage and administration details:

For administration to patients, 4.4 mL of the drug product are added to a 500-mL bottle of commercially available BSS through a syringe filter, resulting in 4.0 mL of the drug product in the 500-mL bottle.

Number of subjects in period 1	OMS302	Placebo
Started	207	209
Completed	202	204
Not completed	5	5
Inadequate preoperative pupil dilation	-	1
Consent withdrawn by subject	3	-
Prohibited preoperative medication	-	1
Adverse event, non-fatal	1	3
Prohibited preoperative eating	1	-

Period 2

Period 2 title	Treated
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst

Blinding implementation details:

None

Arms

Are arms mutually exclusive?	Yes
Arm title	OMS302

Arm description:

OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.

Arm type	Experimental
Investigational medicinal product name	OMS302
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for intraocular irrigation
Routes of administration	Intraocular use

Dosage and administration details:

For administration to patients, 4.4 mL of the drug product are added to a 500-mL bottle of commercially available balanced saline solution (BSS) through a syringe filter, resulting in 4.0 mL of the drug product in the 500-mL bottle.

Arm title	Placebo

Arm description:

Placebo diluted in Balance Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for intraocular irrigation
Routes of administration	Intraocular use

Dosage and administration details:

For administration to patients, 4.4 mL of the drug product are added to a 500-mL bottle of commercially available balanced saline solution (BSS) through a syringe filter, resulting in 4.0 mL of the drug product in the 500-mL bottle.

Number of subjects in period 2	OMS302	Placebo
Started	202	204
Completed	200	201
Not completed	2	3
Physician decision	-	1
Declined to return for final visit.	-	1
Lost to follow-up	2	1

Baseline characteristics

Reporting groups	
Reporting group title	OMS302
Reporting group description: OMS302 diluted in irrigation solution	
Reporting group title	Placebo
Reporting group description: Placebo diluted in irrigation solution	

Reporting group values	OMS302	Placebo	Total
Number of subjects	207	209	416
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	69.2	67.5	
standard deviation	± 9.2	± 10.6	-
Gender categorical Units: Subjects			
Female	120	127	247
Male	87	82	169

Subject analysis sets	
Subject analysis set title	Completed randomization
Subject analysis set type	Intention-to-treat
Subject analysis set description: Subjects who completed randomization.	

Reporting group values	Completed randomization		
Number of subjects	406		
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	68.3		
standard deviation	± 10		
Gender categorical Units: Subjects			
Female	243		
Male	163		

End points

End points reporting groups

Reporting group title	OMS302
Reporting group description:	
OMS302 diluted in irrigation solution	
Reporting group title	Placebo
Reporting group description:	
Placebo diluted in irrigation solution	
Reporting group title	OMS302
Reporting group description:	
OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.	
Reporting group title	Placebo
Reporting group description:	
Placebo diluted in Balance Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.	
Subject analysis set title	Completed randomization
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
Subjects who completed randomization.	

Primary: Mean Area Under the Curve Analysis of Change-from-Baseline in Pupil Diameter (mm) During Surgery

End point title	Mean Area Under the Curve Analysis of Change-from-Baseline in Pupil Diameter (mm) During Surgery
End point description:	
The co-primary analysis of the change in pupil diameter based on the mean area under the curve (AUC) pupil diameter change from baseline. First, the AUC of the pupil diameter from surgical baseline to wound closure was calculated using the trapezoidal rule. Second, the mean AUC was obtained by dividing the AUC by the total time of surgery. Third, the mean AUC of change from baseline was calculated by subtracting the baseline pupil diameter from the mean AUC.	
End point type	Primary
End point timeframe:	
From surgery baseline (pre-incision) through surgery end (time of cortical clean-up/wound closure)	

End point values	OMS302	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	195	200		
Units: mm				
least squares mean (standard deviation)	0.1 (± 0.43)	-0.5 (± 0.57)		

Statistical analyses

Statistical analysis title	1. Primary
Statistical analysis description:	
Statistical Analysis 1 for Mean Area Under the Curve Analysis of Change-from-Baseline in Pupil Diameter	

(mm) During Surgery

Comparison groups	OMS302 v Placebo
Number of subjects included in analysis	395
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	0.59
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.494
upper limit	0.686
Variability estimate	Standard error of the mean
Dispersion value	0.049

Primary: Mean Area Under the Curve Analysis of Ocular Pain VAS Score Within 12 Hours Postoepratively

End point title	Mean Area Under the Curve Analysis of Ocular Pain VAS Score Within 12 Hours Postoepratively

End point description:

The co-primary analysis of the ocular pain VAS (where 0 = no pain and 100 = worst possible pain) based on the mean area under the curve (AUC). The AUC of the ocular pain VAS during 12 hours postoperatively was calculated by the trapezoidal rule in which the hour 11 was used to represent the time-point 10-12 hour. The mean AUC was defined as the AUC divided by the number of hours with ocular pain VAS results during the first 12 hours postoperatively.

End point type	Primary

End point timeframe:

12 hours postoperatively

End point values	OMS302	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	202	202		
Units: pain score				
arithmetic mean (standard deviation)	4.3 (± 8.75)	8.9 (± 15.19)		

Statistical analyses

Statistical analysis title	2. Primary

Statistical analysis description:

Statistical Analysis 1 for Mean Area Under the Curve Analysis of Ocular Pain VAS Score Within 12 Hours Postoperatively

Comparison groups	OMS302 v Placebo

Number of subjects included in analysis	404
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0002
Method	Cochran-Mantel-Haenszel
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.917
upper limit	-2.244
Variability estimate	Standard error of the mean
Dispersion value	1.192

Secondary: Pupil Diameter Greater Than or Equal to 6 mm at Completion of Cortical Clean up

End point title	Pupil Diameter Greater Than or Equal to 6 mm at Completion of Cortical Clean up

End point description:

The number of subjects with pupil diameter of at least 6 mm at the completion of cortical clean up summarized by treatment arm. The last pupil diameter was used if not available at completion of cortical clean up.

End point type	Secondary

End point timeframe:

at time of cortical clean-up (i.e., end of surgical procedure)

End point values	OMS302	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	195	200		
Units: participants	187	154		

Statistical analyses

Statistical analysis title	3. Secondary

Statistical analysis description:

Statistical Analysis 1 for Pupil Diameter Greater Than or Equal to 6 mm at Completion of Cortical Clean up

Comparison groups	OMS302 v Placebo
Number of subjects included in analysis	395
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Chi-squared

Secondary: Pupil Diameter Less Than 6 mm Anytime During Surgery

End point title	Pupil Diameter Less Than 6 mm Anytime During Surgery

End point description:

The number of subjects with pupil diameter less than 6 mm at any time during surgery summarized by treatment arm

End point type	Secondary

End point timeframe:

Intraoperative

End point values	OMS302	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	195	200		
Units: participants	18	76		

Statistical analyses

Statistical analysis title	4. Secondary

Statistical analysis description:

Statistical Analysis 1 for Pupil Diameter Less Than 6 mm Anytime During Surgery

Comparison groups	OMS302 v Placebo
Number of subjects included in analysis	395
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Chi-squared

Secondary: Moderate-to-Severe Pain (VAS Greater Than or Equal to 40) at Any Time Point During 12 Hours Postoperatively

End point title	Moderate-to-Severe Pain (VAS Greater Than or Equal to 40) at Any Time Point During 12 Hours Postoperatively

End point description:

Moderate-to-Severe Pain (VAS Greater Than or Equal to 40) at Any Time Point During 12 Hours Postoperatively

End point type	Secondary

End point timeframe:

12 hours postoperatively

End point values	OMS302	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	202	202		
Units: participants	16	27		

Statistical analyses

Statistical analysis title	5. Secondary

Statistical analysis description:

Statistical Analysis 1 for Moderate-to-Severe Pain (VAS Greater Than or Equal to 40) at Any Time Point During 12 Hours Postoperatively

Comparison groups	OMS302 v Placebo
Number of subjects included in analysis	404
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.076
Method	Chi-squared

Secondary: Ocular Pain-Free (VAS Equal to 0) at All Time Points During 12 Hours Postoperatively

End point title	Ocular Pain-Free (VAS Equal to 0) at All Time Points During 12 Hours Postoperatively

End point description:

The number of subjects who report ocular pain-free status (VAS equal to 0) at all time points during 12 hours postoperatively summarized by treatment arm. Subjects with missing VAS scores during the 12 hours postoperatively were considered as not being pain-free.

End point type	Secondary

End point timeframe:

12 hours postoperatively

End point values	OMS302	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	202	202		
Units: participants	56	41		

Statistical analyses

Statistical analysis title	6. Secondary

Statistical analysis description:

Statistical Analysis 1 for Ocular Pain-Free (VAS Equal to 0) at All Time Points During 12 Hours Postoperatively

Comparison groups	OMS302 v Placebo

Number of subjects included in analysis	404
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0806
Method	Chi-squared

Secondary: Ocular Pain VAS Score on Day 1

End point title	Ocular Pain VAS Score on Day 1

End point description:

VAS pain scores (where 0 = no pain and 100 = worst possible pain) after the day of surgery summarized by treatment arm and time point.

End point type	Secondary

End point timeframe:

One day postoperatively

End point values	OMS302	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	202	204		
Units: units on a scale				
arithmetic mean (standard deviation)	5.8 (± 13.1)	12.2 (± 20.1)		

Statistical analyses

Statistical analysis title	7. Secondary

Statistical analysis description:

Statistical Analysis 1 for Ocular Pain VAS Score on Day 1

Comparison groups	OMS302 v Placebo
Number of subjects included in analysis	406
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0002
Method	Cochran-Mantel-Haenszel

Secondary: Ocular Symptoms Using Numerical Rating System (NRS) – Photophobia 6 Hours Post-Surgery

End point title	Ocular Symptoms Using Numerical Rating System (NRS) – Photophobia 6 Hours Post-Surgery

End point description:

Photophobia outcomes based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System – NRS) at each time point.

End point type	Secondary

End point timeframe:

Six hours postoperatively

End point values	OMS302	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	200	202		
Units: participants				
None	140	128		
Mild	51	58		
Moderate	8	13		
Severe	1	3		

Statistical analyses

Statistical analysis title	8. Secondary

Statistical analysis description:

Statistical Analysis 1 for Ocular Symptoms Using Numerical Rating System (NRS) – Photophobia 6 Hours Post-Surgery

Comparison groups	OMS302 v Placebo
Number of subjects included in analysis	402
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.3923
Method	Cochran-Mantel-Haenszel

Secondary: Ocular Symptoms Using Numerical Rating System (NRS) – Photophobia 1 Day Post-Surgery

End point title	Ocular Symptoms Using Numerical Rating System (NRS) – Photophobia 1 Day Post-Surgery

End point description:

Photophobia outcomes based on Ocular Pain and Symptoms Numerical Ordinal Scale (Numerical Rating System – NRS) at each time point.

End point type	Secondary

End point timeframe:

One day postoperatively

End point values	OMS302	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	202	204		
Units: participants				
None	119	95		
Mild	63	63		
Moderate	16	37		
Severe	4	9		

Statistical analyses

Statistical analysis title	9. Secondary

Statistical analysis description:

Statistical Analysis 1 for Ocular Symptoms Using Numerical Rating System (NRS) – Photophobia 1 Day Post-Surgery

Comparison groups	OMS302 v Placebo
Number of subjects included in analysis	406
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.006
Method	Cochran-Mantel-Haenszel

Secondary: Postoperative Ocular Inflammation - Mean Summed Ocular Inflammation Score (SOIS) on Day 1

End point title	Postoperative Ocular Inflammation - Mean Summed Ocular Inflammation Score (SOIS) on Day 1

End point description:

Postoperative inflammation as measured using the Summed Ocular Inflammation Score (SOIS), summarized by treatment arm and time point. Ocular inflammation was evaluated by measuring the anterior chamber cell count and flare using a slit lamp biomicroscope. SOIS was calculated by adding the average of subject's anterior chamber cells and flare grades. The minimum SOIS was 0 (indicating absence of inflammation), whereas the maximum SOIS was 8.

Grading was as follows:

Anterior Chamber Cells: Grade None = 0/no cells; Grade Mild = +1/1-5 cells; Grade Moderate = +2/6-15 cells; Grade Severe = +3/16-30 cells; Grade Very Severe = +4/>30 cells.

Anterior Chamber Flare: Grade None = 0/no Tyndall effect; Grade Mild = +1/barely discernable Tyndall effect; Grade Moderate = +2/moderately intense Tyndall beam in anterior chamber; Grade Severe = +3/severely intense Tyndall beam; Grade Very Severe = +4/very severely intense Tyndall beam with a white and milky appearance to the aqueous

End point type	Secondary

End point timeframe:

One day postoperatively

End point values	OMS302	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	202	204		
Units: SOIS				
arithmetic mean (standard deviation)	2.8 (± 1.0)	2.9 (± 1.3)		

Statistical analyses

Statistical analysis title	10. Secondary
Statistical analysis description:	
Statistical Analysis 1 for Postoperative Ocular Inflammation - Mean Summed Ocular Inflammation Score (SOIS) on Day 1	
Comparison groups	OMS302 v Placebo
Number of subjects included in analysis	406
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.3286
Method	Cochran-Mantel-Haenszel

Secondary: Postoperative Best Corrected Visual Acuity (BVCA) on Day 1

End point title	Postoperative Best Corrected Visual Acuity (BVCA) on Day 1
End point description:	
Best Corrected Visual Acuity (BCVA) summarized by the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity log score. The reason for missing scores (e.g., subject could not read enough letters to obtain a score or refraction was not completed) was also summarized. For subjects without a score due to inability to read the ETDRS chart, the log score was imputed as 1.6 for the purpose of treatment comparisons. Subjects without a score because the manifest refraction was not completed were excluded from the analysis.	
End point type	Secondary
End point timeframe:	
One day postoperatively	

End point values	OMS302	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	201	203		
Units: BCVA Score				
arithmetic mean (standard deviation)	0.1 (± 0.20)	0.1 (± 0.18)		

Statistical analyses

Statistical analysis title	11. Secondary
Statistical analysis description:	
Statistical Analysis 1 for Postoperative Best Corrected Visual Acuity (BVCA) on Day 1	

Comparison groups	OMS302 v Placebo
Number of subjects included in analysis	404
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.2361
Method	Wilcoxon rank-sum test

Secondary: Systemic Pharmacokinetics (PK) of OMS302

End point title	Systemic Pharmacokinetics (PK) of OMS302

End point description:

Systemic pharmacokinetics (PK) of phenylephrine (PE) and ketorolac (KE) were performed in a subset of subjects. Descriptive summary statistics for area-under-the-serum-concentration-time curve (AUC), maximum concentration (Cmax), time to Cmax (Tmax), and terminal phase half-life (t1/2) were to be generated if measured plasma concentrations were adequate for analysis. Descriptive statistics for pharmacokinetics were not performed as detected concentrations were low and insufficient for analysis.

End point type	Secondary

End point timeframe:

24 hours

End point values	OMS302	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	12		
Units: participants				
Subjects with detectable PE	1	0		
Subjects with detectable KE	10	1		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

90 days

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	14.1

Reporting groups

Reporting group title	OMS302

Reporting group description:

OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.

OMS302: OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 60.75 mM phenylephrine HCl and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product are added to a 500-mL bottle of commercially available BSS through a syringe filter, resulting in 4.0 mL of the drug product in the 500-mL bottle.

Reporting group title	Placebo

Reporting group description:

Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.

Placebo: Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter, resulting in 4.0 mL of the drug product in the 500-mL bottle.

Serious adverse events	OMS302	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 202 (0.99%)	2 / 204 (0.98%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lung neoplasm malignant			
subjects affected / exposed	0 / 202 (0.00%)	1 / 204 (0.49%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Myocardial infarction			

subjects affected / exposed	1 / 202 (0.50%)	0 / 204 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	0 / 202 (0.00%)	1 / 204 (0.49%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Respiratory arrest			
subjects affected / exposed	0 / 202 (0.00%)	1 / 204 (0.49%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 202 (0.50%)	0 / 204 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0.05 %

Non-serious adverse events	OMS302	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	118 / 202 (58.42%)	143 / 204 (70.10%)	
Investigations			
Intraocular pressure increased			
subjects affected / exposed	12 / 202 (5.94%)	4 / 204 (1.96%)	
occurrences (all)	12	4	
Nervous system disorders			
Headache			
subjects affected / exposed	21 / 202 (10.40%)	24 / 204 (11.76%)	
occurrences (all)	21	24	
Eye disorders			
Eye pain			
subjects affected / exposed	34 / 202 (16.83%)	76 / 204 (37.25%)	
occurrences (all)	34	76	
Posterior capsule opacification			

subjects affected / exposed	17 / 202 (8.42%)	14 / 204 (6.86%)	
occurrences (all)	17	14	
Anterior chamber inflammation			
subjects affected / exposed	17 / 202 (8.42%)	13 / 204 (6.37%)	
occurrences (all)	17	13	
Ocular discomfort			
subjects affected / exposed	10 / 202 (4.95%)	15 / 204 (7.35%)	
occurrences (all)	10	15	
Vision blurred			
subjects affected / exposed	5 / 202 (2.48%)	16 / 204 (7.84%)	
occurrences (all)	5	16	
Conjunctival hyperaemia			
subjects affected / exposed	10 / 202 (4.95%)	10 / 204 (4.90%)	
occurrences (all)	10	10	
Photophobia			
subjects affected / exposed	4 / 202 (1.98%)	13 / 204 (6.37%)	
occurrences (all)	4	13	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported